Resources>Antibody Industry Trends>Biointron Insights: Antibody Industry Report (Q3 2025 Insights, Trends & Analysis)

Biointron Insights: Antibody Industry Report (Q3 2025 Insights, Trends & Analysis)

Biointron 2025-10-01

q3 linkrfin ad.png

Biointron’s Q3 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, 2 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: both from China.

  1. Firsekibart (Jin Beixin)

  2. Suvemcitug (Enzheshu)

Q3 2025 saw various acquisitions, collaborations, and licensing agreements of up to US$8 billion. Investment into antibody drug startups has focused on artificial intelligence platforms and antibody bispecific formats.

Gain exclusive insights into current trends such as:

  • 2 novel antibody drugs approved for the first time in Q3

  • Top 10 antibody drug deals, including acquisitions, licensing agreements, and collaborations of up to US$8B

  • Current research into designing antibodies from scratch (de novo)

  • Immune cell engagers as a bispecific antibody format

  • A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q4 2025


Please fill in the form below to download


Recommended Articles
Biointron Insights: Antibody Industry Trends (Q3 2026 Insights, Trends & Analysis)

Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……

Sep 30, 2026
November 2026: Bispecifics x AI: From Design to Clinic

Bispecific antibodies (BsAbs) can bind two different antigens simultaneously, of……

Nov 09, 2026
Week 1, November 2026: VNAR vs. VHH: What's the Difference Between Shark and Camelid Single-Domain Antibodies?

When we think of antibodies, sharks and alpacas probably aren't the first an……

Nov 03, 2026
Week 3, October 2026: The Evolving Role of Biomarkers in Antibody-Based Cancer Therapies

Antibody-based cancer therapies have expanded treatment options across multiple ……

Oct 21, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.